Daniela Perani
Overview
Explore the profile of Daniela Perani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
229
Citations
4713
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Salemme S, Lombardo F, Lacorte E, Sciancalepore F, Remoli G, Bacigalupo I, et al.
Alzheimers Dement (Amst)
. 2025 Mar;
17(1):e70074.
PMID: 40078377
Introduction: Knowledge gaps remain about the prognosis of mild cognitive impairment (MCI). Conversion rates to dementia vary widely, and reversion to normal cognition has gained attention. This review updates evidence...
2.
Caminiti S, Avenali M, Galli A, Malito R, Cuconato G, Galandra C, et al.
NPJ Parkinsons Dis
. 2025 Mar;
11(1):41.
PMID: 40038314
We evaluated 128 GBA and 432 nonGBA Parkinson's disease (PD) subjects available from Parkinson's Progression Markers Initiative. Baseline clinical features and dopaminergic activity were assessed, together with clinical follow-up (6.87 ...
3.
Carrarini C, Caraglia N, Quaranta D, Vecchio F, Miraglia F, Giuffre G, et al.
Eur J Neurol
. 2025 Feb;
32(2):e16591.
PMID: 39895250
Background: The Italian Interceptor project is aimed at identifying a prodromal dementia phase and developing a nationwide organizational model. This study compares the sociodemographic and neuropsychological characteristics of mild cognitive...
4.
Pilotto A, Galli A, Sala A, Caminiti S, Presotto L, Liguori C, et al.
Mol Psychiatry
. 2025 Jan;
PMID: 39890920
Both post-mortem and in vivo data argue for dopamine dysfunction in patients with Alzheimer's Disease (AD). However, the timing and regional progression of dopaminergic systems alterations in AD are still...
5.
Boccalini C, Peretti D, Mathoux G, Iaccarino L, Ribaldi F, Scheffler M, et al.
Eur J Nucl Med Mol Imaging
. 2025 Jan;
PMID: 39849149
Purpose: As dual-phase amyloid-PET can evaluate amyloid (A) and neurodegeneration (N) with a single tracer injection, dual-phase tau-PET might be able to provide both tau (T) and N. Our study...
6.
Catania M, Battipaglia C, Perego A, Salvi E, Maderna E, Cazzaniga F, et al.
Fluids Barriers CNS
. 2025 Jan;
22(1):9.
PMID: 39838411
Background: The approval of new disease-modifying therapies by the U.S. Food and Drug Administration and the European Medicine Agency makes it necessary to optimize non-invasive and cost-effective tools for the...
7.
Boccalini C, Dodich A, Scheffler M, Lagana V, Fratto E, Frisoni G, et al.
Neurology
. 2024 Nov;
103(12):e210103.
PMID: 39586047
Objectives: We investigated tau and neurodegeneration patterns and clinical phenotypes in carriers of a specific pathogenic variant in the PSEN1 gene and 1 nonaffected relative. Methods: We included 3 symptomatic...
8.
Pilotto A, Galli A, Zatti C, Placidi F, Izzi F, Premi E, et al.
Ann Clin Transl Neurol
. 2024 Oct;
11(11):2836-2845.
PMID: 39444171
Methods: This study assessed data from two cohorts of patients with alpha-synucleinopathies (University of Brescia and University of Rome Tor-Vergata cohorts). Consecutive participants with video-polysomnography-confirmed iRBD, Parkinson's disease (PD), dementia...
9.
Silani G, Aglioti S, Perani D
Front Integr Neurosci
. 2024 Oct;
18:1495554.
PMID: 39411706
No abstract available.
10.
Martini A, Carli G, Caminiti S, Kiferle L, Leo A, Perani D, et al.
Eur J Nucl Med Mol Imaging
. 2024 Oct;
52(3):810-822.
PMID: 39404791
Purpose: Our study examines brain metabolic connectivity in SARS-CoV-2 survivors during the acute-subacute and chronic phases, aiming to elucidate the mechanisms underlying the persistence of neurological symptoms in long-COVID patients....